{
  "content": "Comment \nAmiodarone can be used to safely treat supraventricular and ventricular arrhythmias. It usually does not exacerbate CHF and is rarely proarrhythmic. The unique pharmacokinetics and pharmacodynamics of amiodarone make it difficult to predict individual patient responses. Substantial cardiac and noncardiac adverse effects may (rarely) be fatal. Important drug-drug interactions frequently complicate management.",
  "source": "https://jamanetwork.com/journals/jama/fullarticle/208819",
  "chunk_id": "56a35830-2e37-4e86-8ce9-c7eb2f3040c6",
  "similarity_score": 0.25852346420288086,
  "query": "amiodarone pharmacokinetics drug interactions CYP450 beta-blockers metabolism clearance atrial fibrillation dosing",
  "rank": 48,
  "title": "Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications",
  "authors": "Patricia Vassallo, Richard G. Trohman",
  "year": "2007",
  "journal": "JAMA",
  "reference": "Vassallo, P., & Trohman, R. G. (2007). Prescribing amiodarone: An evidence-based review of clinical indications. JAMA, 298(11), 1312-1322. https://doi.org/10.1001/jama.298.11.1312",
  "doi": "10.1001/jama.298.11.1312",
  "chunk_index": 121,
  "total_chunks": 177,
  "retrieved_at": "2025-07-24T21:58:09.739296"
}